ClinicalTrials.Veeva

Menu

Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives (HEPAGLY)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Liver Fibrosis

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.

Enrollment

30 estimated patients

Sex

All

Ages

1 month to 21 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Minors: from birth to 17 years
  • Adults: 18 to 21 years
  • Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up.

Exclusion criteria

- Patients monitored for type III glycogen storage disease but who had never undergone liver elastography during their follow-up.

Trial contacts and locations

1

Loading...

Central trial contact

Camille WICKER, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems